blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4021432

EP4021432 - ESKETAMINE FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  03.06.2022
Database last updated on 03.10.2024
FormerThe international publication has been made
Status updated on  05.03.2021
Most recent event   Tooltip05.07.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Janssen Pharmaceuticals, Inc.
1125 Trenton-Harbourton Road
Titusville, NJ 08560 / US
[2022/27]
Inventor(s)01 / CANUSO, Carla M.
1125 Trenton-Harbourton Road Titusville
New Jersey 08560 / US
02 / FU, Dong-Jing
1125 Trenton-Harbourton Road Titusville
New Jersey 08560 / US
03 / IONESCU, Dawn F.
1125 Trenton-Harbourton Road Titusville
New Jersey 08560 / US
04 / LANE, Roseanne
1125 Trenton-Harbourton Road Titusville
New Jersey 08560 / US
 [2022/27]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2022/27]
Application number, filing date20857872.428.08.2020
[2022/27]
WO2020IB58030
Priority number, dateUS201962892841P28.08.2019         Original published format: US 201962892841 P
US201962897593P09.09.2019         Original published format: US 201962897593 P
[2022/27]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2021038500
Date:04.03.2021
Language:EN
[2021/09]
Type: A2 Application without search report 
No.:EP4021432
Date:06.07.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 04.03.2021 takes the place of the publication of the European patent application.
[2022/27]
Search report(s)International search report - published on:US22.04.2021
(Supplementary) European search report - dispatched on:EP14.07.2023
ClassificationIPC:A61K31/135, A61K45/06, A61P25/24, A61K9/00, A61K9/08
[2023/33]
CPC:
A61K31/135 (EP,US); A61K45/06 (EP,US); A61K9/0014 (EP);
A61K9/0043 (US); A61K9/08 (EP,US); A61P25/24 (EP,US)
Former IPC [2022/27]A61K31/135, A61K45/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/27]
Extension statesBA28.03.2022
ME28.03.2022
TitleGerman:ESKETAMIN ZUR BEHANDLUNG VON PATIENTEN MIT STARKER DEPRESSIVER STÖRUNG, EINSCHLIESSLICH SUIZIDALITÄT[2022/27]
English:ESKETAMINE FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY[2022/27]
French:ESKÉTAMINE POUR LE TRAITEMENT DE PATIENTS PRÉSENTANT UN TROUBLE DÉPRESSIF MAJEUR, NOTAMMENT LA SUICIDALITÉ[2022/27]
Entry into regional phase28.03.2022National basic fee paid 
28.03.2022Search fee paid 
28.03.2022Designation fee(s) paid 
28.03.2022Examination fee paid 
Examination procedure28.03.2022Examination requested  [2022/27]
09.02.2024Date on which the examining division has become responsible
05.03.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
03.05.2024Amendment by applicant (claims and/or description)
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
03.05.2024Request for further processing filed
03.05.2024Full payment received (date of receipt of payment)
Request granted
14.05.2024Decision despatched
Fees paidRenewal fee
28.03.2022Renewal fee patent year 03
05.07.2023Renewal fee patent year 04
04.07.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO2016172672  (ICAHN SCHOOL MED MOUNT SINAI [US]) [X] 1,3,5 * pages 7,8 * * claims 1-6,11 * [Y] 1-10;
 [XY]  - AJUB ELIAS ET AL, "Efficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series", BIOLOGICAL PSYCHIATRY, (20180101), vol. 83, no. 1, doi:10.1016/J.BIOPSYCH.2017.06.011, ISSN 0006-3223, XP085287211 [X] 1,3-5 * page e15 * * table 1 * [Y] 1-10

DOI:   http://dx.doi.org/10.1016/j.biopsych.2017.06.011
 [XY]  - BJERRE J ET AL, "Ketamine in melancholic depression", UGESKRIFT FOR LAEGER, DK, (20100208), vol. 172, no. 6, doi:https://pubmed.ncbi.nlm.nih.gov/20146912/, ISSN 0041-5782, pages 460 - 461, XP093061580 [X] 1,3,5,7 * abstract * * Enclosed automatic translation * [Y] 1-10

DOI:   http://dx.doi.org/https://pubmed.ncbi.nlm.nih.gov/20146912/
 [Y]  - CARLA M CANUSO ET AL, "Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study", AMERICAN JOURNAL OF PSYCHIATRY., US, (20180411), vol. 175, no. 7, doi:10.1176/appi.ajp.2018.17060720, ISSN 0002-953X, pages 620 - 630, XP055575012 [Y] 1-10 * abstract * * tables 1-2 * * figures 1-4 *

DOI:   http://dx.doi.org/10.1176/appi.ajp.2018.17060720
 [Y]  - REBECCA B PRICE ET AL, "EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION", DEPRESSION AND ANXIETY, NEW YORK, NY, US, (20140325), vol. 31, no. 4, doi:10.1002/DA.22253, ISSN 1091-4269, pages 335 - 343, XP072006337 [Y] 1-10 * abstract * * figure 2 * * page 341, column left *

DOI:   http://dx.doi.org/10.1002/da.22253
International search[A]US2013236573  (SINGH JASKARAN [US], et al) [A] 1-4, 11-14 * entire document *;
 [A]US2016074340  (CAERS LODEWIJK IVO [BE], et al) [A] 1-4, 11-14 * entire document *;
 [X]US2016338977  (SINGH JASKARAN [US], et al) [X] 1-4, 11-14 * abstract, para [0026], (0030], [0110] *;
 [A]WO2019126108  (JANSSEN PHARMACEUTICA NV [BE], et al) [A] 1-4, 11-14* entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.